Qingzhi Wu, NP

Qingzhi Wu practices at ProMedica Skilled Nursing and Rehabilitation (Sunnyvale) in Sunnyvale, California.

Qingzhi Wu's NPI, 1144982935, was assigned on October 8, 2021. Qingzhi Wu holds California license NP95018255.

Qingzhi Wu's primary practice is ProMedica Skilled Nursing and Rehabilitation (Sunnyvale), at 1150 Tilton Dr, Sunnyvale, CA 94087 in Santa Clara County. The practice phone is (408) 735-7200.

Qingzhi Wu's primary practice is ProMedica Skilled Nursing and Rehabilitation (Sunnyvale) in Sunnyvale, California. The medical group on file is Quality Care Solution. Dmand AI also links Qingzhi Wu to 1 more skilled nursing facility, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Qingzhi Wu practices. Vendor and product names are available with a free account.

Family is Qingzhi Wu's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Qingzhi Wu is licensed in California.

Dmand AI lists ADHD, alcohol use disorders, alzheimer's disease, anxiety, arthritis, asthma, benign or precancerous skin growths and bipolar disorder among the conditions Qingzhi Wu treats.

CMS data shows 12,875 Medicare services from Qingzhi Wu across 5 procedure codes in 2024, for 482 Medicare patients. Medicare paid $956,901 for them. Every service was in an office.

CMS counts 482 Medicare patients who saw Qingzhi Wu in 2024. The largest group is 75 to 84, with 156 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 69% are also on Medicaid. Their average risk score is 3.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Qingzhi Wu's median patient age at 79, with 52% women.

In 2024, Qingzhi Wu wrote 554 Medicare Part D claims for 85 patients. 75% of them were for generic drugs. CMS names the drug for 412 of them, across 14 drugs with 11 or more claims each, at $26,067 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 18 out of 100 for Qingzhi Wu for performance year 2024, reported individually. Qingzhi Wu accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 5 general payments to Qingzhi Wu from 4 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $126.